In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results < Back to Main

Page Options

  • Print This Page
  • Email This Document

Search Trial Results

Breast Cancer Trial Results


For Some Breast Cancers, New Drug May Be Treatment Option
(Posted: 06/13/2012, Updated: 11/29/2012) - Results from an international clinical trial suggest that women with metastatic, HER2-positive breast cancer that is no longer responding to the targeted therapy trastuzumab (Herceptin) may soon have a new treatment option. Women who received the investigational drug trastuzumab emtansine (T-DM1) lived more than 3 months longer without their tumors progressing than women who received the chemotherapy drug capecitabine (Xeloda) and the targeted drug lapatinib (Tykerb).

Exercise, Behavioral Therapy Reduce Menopausal Symptoms Caused by Breast Cancer Treatment
(Posted: 10/25/2012) - Women with breast cancer who were suffering from treatment-related menopausal symptoms experienced symptom relief with cognitive behavioral therapy, physical exercise, or both, according to a Dutch study published October 8, 2012, in the Journal of Clinical Oncology.

Exemestane Reduces Breast Cancer Risk in High-Risk Postmenopausal Women
(Posted: 07/19/2011, Updated: 03/07/2012) - Clinical trial results presented at the 2011 ASCO annual meeting showed that the aromatase inhibitor exemestane (Aromasin®)—commonly used to treat early and advanced-stage breast cancer—substantially reduced the risk of invasive breast cancer in postmenopausal women at high risk of developing the disease.

Exemestane Following Tamoxifen Reduces Breast Cancer Recurrences and Prolongs Survival
(Posted: 02/01/2012) - Long-term follow-up data from a large international phase III trial shows that postmenopausal women with early-stage hormone receptor-positive breast cancer who received 2 to 3 years of tamoxifen and then switched to the drug exemestane (Aromasin®) for a total of 5 years of adjuvant hormone therapy experienced a delay in disease recurrence and a survival advantage, compared with women who took tamoxifen for 5 years.

Combination Therapy Shows Promise for Treating Advanced Breast Cancer
(Posted: 12/21/2011) - Adding the drug everolimus (Afinitor®) to exemestane helped postmenopausal women whose advanced breast cancer had stopped responding to hormonal therapy live about 4 months longer without the disease progressing than women who received exemestane alone.

< Previous  1 2 3 4 5 6 7 8 9  Next >